Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
Manoj K/ LinkedIn
Jun 8, 2026, 06:02

Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease

Manoj K, Senior Partner and Life Sciences Industry Leader at IBM Consulting, shared a post on LinkedIn:

“Twice a week. Every week. For life. That has been the burden for patients with von Willebrand disease (VWD), the most common inherited bleeding disorder more prevalent than hemophilia A and B combined.

While hemophilia advanced with gene therapies and extended factors, VWD patients relied on frequent IV plasma-derived concentrates, unchanged since the 1980s. That changed with today’s news.

Incyte is nearing a deal to acquire Star Therapeutics for up to $2B ($1.25B upfront plus $750M milestones). The prize: VGA039, a first-in-class once-monthly subcutaneous monoclonal antibody self-administered at home, no IV, no hospital.

At the center of the deal is VGA039 Star’s first-in-class monoclonal antibody targeting Protein S, currently in pivotal Phase 3 trials for von Willebrand disease.

The therapy, known as VGA039, is in late-stage clinical testing and has received Fast Track designation from the U.S. FDA. For Incyte, this is the hematology anchor their post-Jakafi pipeline has been missing.

The human stakes are straightforward. Today’s VWD patients endure two to three IV infusions every week hospital-dependent, schedule-disrupting, relentless.

VGA039 replaces that entirely with a once-monthly subcutaneous injection, self-administered at home. Same protection. A fraction of the burden.

The acquisition would also mark the first major deal under Incyte CEO Bill Meury, who took over last year and has emphasized acquisitions as a way to offset future revenue pressure from the expected 2028 patent expiration of the company’s top-selling blood cancer drug, Jakafi.

Star Therapeutics backed by Sofinnova Partners, RA Capital Management, and Catalio Capital Management had explored an IPO before the math of a strategic sale proved more compelling.

Incyte‘s expertise in blood disorders could help position the company to commercialize VGA039 if it wins regulatory approval.”

Stay updated with Hemostasis Today.

Bill Meury Catalio Capital Management Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Incyte Jakafi Manoj K Medicine RA Capital Management Sofinnova Partners Star Therapeutics VWD
NewsFeed